Financial Analysis: Regenicin (OTCMKTS:RGIN) and Surmodics (NASDAQ:SRDX)

Surmodics (NASDAQ:SRDX) and Regenicin (OTCMKTS:RGIN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings and analyst recommendations.

Profitability

This table compares Surmodics and Regenicin’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Surmodics	9.44%	13.30%	8.63%
Regenicin	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Surmodics and Regenicin, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surmodics	0	4	0	0	2.00
Regenicin	0	0	0	0	N/A

Surmodics currently has a consensus price target of $50.00, suggesting a potential upside of 19.22%.

Volatility & Risk

Surmodics has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500. Comparatively, Regenicin has a beta of -18.89, indicating that its stock price is 1,989% less volatile than the S&P 500.

Earnings and Valuation

This table compares Surmodics and Regenicin’s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surmodics	$132.58 million	4.51	-$1.54 million	$0.95	44.15
Regenicin	N/A	N/A	-$640,000.00	N/A	N/A

Regenicin has lower revenue, but higher earnings than Surmodics.

Insider & Institutional Ownership

96.6% of Surmodics shares are owned by institutional investors. Comparatively, 0.0% of Regenicin shares are owned by institutional investors. 8.9% of Surmodics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Surmodics beats Regenicin on 7 of the 8 factors compared between the two stocks.

About Surmodics

Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.

About Regenicin

Regenicin, Inc. focuses on developing and commercializing a technology of tissue-engineered skin substitutes. Its product portfolio includes NovaDerm, a multi-layered tissue-engineered living skin and cultured skin substitute product for the treatment of burns; and TempaDerm to treat smaller wound areas on patients, such as ulcers. The company products are used to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds, and various plastic surgery procedures. The company was formerly known as Windstar, Inc. and changed its name to Regenicin, Inc. in July 2010. Regenicin, Inc. was incorporated in 2007 and is headquartered in Little Falls, New Jersey.